Company intelligence / Profile preview

Jyong Biotech Ltd.

New Taipei City, Taiwanjyongir.com ↗

Ownership: Private
Employees: ~31
Development stage: Phase 3

Overview

Jyong Biotech is a Taiwan-based biotech company focused on developing plant-derived drugs for urinary system diseases. Its lead candidate, MCS-2, is in Phase III trials for BPH/LUTS with an NDA resubmission planned after addressing FDA comments. Other pipeline assets include PCP (Phase II, prostate cancer prevention) and IC (preclinical, interstitial cystitis). The company recently raised $20 million via a Nasdaq IPO to fund advanced clinical trials.

Therapeutic areas: OncologyNephrologyMen's Health
Modalities: Plant-derived drugsNanocarrier-based formulations (micelles)
Industry: Biotech

Drug pipeline

3 assets

MCS-2

2 more assets in the full pipeline.

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of June 2025; Joseph Stone Capital served as sole underwriter for the IPO

Beyond the preview

Go deeper on Jyong Biotech Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jyong Biotech Ltd..